UY

Urvi Yash Panchal

Active Director Designated Partner DIN 10818172
DIN 10818172 First appointment Oct 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Oct 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Urvi Yash Panchal

Data last updated:

Urvi Yash Panchal is a Designated Partner at Clinscript Experts Llp (since 2024) and Designated Partner at Clinpen Insight Medical Writing Agency Llp (since 2024).

DIN 10818172
Primary Designation Designated Partner
First Appointment 23 Oct 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner28 Oct 20242024Active
Designated Partner23 Oct 20242024Active

Board colleagues of Urvi Yash Panchal

Directorship timeline

Open interactive timeline →
Clinscript Experts Llp
Clinpen Insight Medical Writing Agency Llp
Premium access

Shareholding and investment profile for Urvi Yash Panchal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Urvi Yash Panchal

Urvi Yash Panchal currently holds 2 directorships: Clinscript Experts Llp (Designated Partner, since 28 Oct 2024); Clinpen Insight Medical Writing Agency Llp (Designated Partner, since 23 Oct 2024).

Urvi Yash Panchal was first appointed on 23 Oct 2024 as Designated Partner at Clinpen Insight Medical Writing Agency Llp.

The current boards of Urvi Yash Panchal's companies include Archi Panchal (Clinscript Experts Llp), Yash Panchal (Clinscript Experts Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available